Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Charles River Laboratories (CRL) , which belongs to the Zacks Medical Services industry. This medical research equipment and services provider has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 13.94%. For the last reported quarter, Charles River came ou ...

Charles River Laboratories International, Inc. (CRL) is scheduled to report third-quarter 2024 results on Nov. 6, before market open.In the last reported quarter, the company’s adjusted earnings per share of $2.80 surpassed the Zacks Consensus Estimate by 17.2%. Earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.64%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.CRL’s Q3 EstimatesThe Zacks Consensus Estimate for revenues is pegged ...

PHILADELPHIA, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Ori Biotech (Ori), a leader in cell and gene therapy (CGT) manufacturing enabling technology, and Charles River Laboratories (Charles River), a global industryleading drug discovery, preclinical development, manufacturing and testing solutions provider, today announced a collaboration to demonstrate the benefits of Ori's next-generation CGT manufacturing platform, IRO®(eeRO). In early 2024, Ori and Charles River collaborated through Ori's LightSpeed Early Acc ...

Charles River Laboratories International, Inc. (CRL) and Insightec announced a five-year strategic collaboration to advance the applications of focused ultrasound (FUS) for drug discovery and preclinical development of therapeutics in neuroscience. Under the partnership, Charles River's clients will gain access to Insightec's novel low-frequency ultrasound platform, which non-invasively disrupts the blood-brain barrier, enabling drugs to be delivered to targeted brain areas. The latest development is expect ...

It has been about a month since the last earnings report for Charles River Laboratories (CRL) . Shares have lost about 5.3% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Charles River due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Charles River Q2 Earnings Bea ...

I I F ■ F Matteo Colombo Investment update Following my last publication on Charles River Laboratories International, Inc. (NYSE:CRL) in May, the business is -3% to the downside and after its Q2 FY'24 numbers, I've revised my rating on the company to a hold for reasons outlined in this note. Critically, my view in May was formed on a potential turnaround in the economic situation of the business, along with operating growth that required very little incremental capital to produce. On reflection, this may ha ...

NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Charles River Laboratories International, Inc. (NYSE: CRL) on behalf of long-term stockholders following a class action complaint that was filed against Charles River on May 19, 2023 with a Class Period from May 5, 2020 to February 21, 2023. Our investigation concerns whether the board of directors of Charles River have breached their fiducia ...

Have you looked into how Charles River Laboratories (CRL) performed internationally during the quarter ending June 2024? Considering the widespread global presence of this medical research equipment and services provider, examining the trends in international revenues is essential for assessing its financial resilience and prospects for growth. The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and g ...

Solskin I highlighted Charles River Laboratories's (NYSE:CRL) near-term challenges due to the weak biopharma market, initiating with a 'Hold' rating in my previous coverage published in February 2024. The company released its Q2 result on August 7th, lowering its full-year guidance due to weak demands from small and mid-sized biotechnology customers. I think the current stock price has already factored in the softness of biopharma market, making it an opportune time to invest in this highquality company. Th ...

Charles River Laboratories International, Inc. (CRL) reported second-quarter 2024 adjusted earnings per share (EPS) of $2.80, which increased 4.1% year over year. The figure surpassed the Zacks Consensus Estimate by 17.2%. On a GAAP basis, earnings declined 7.9% year over year to $1.74 per share. Revenues Revenues totaled $1.03 billion, in line with the Zacks Consensus Estimate. However, the top line declined 2.8% from the year-ago quarter's level (down 3.2% organically, excluding the impact of acquisition, ...